CALL/AMGEN/450/0.1/16.08.24 Stock

DE000GG4ZF82

Real-time BOERSE MUENCHEN 04:25:53 2024-05-29 am EDT
0.021 ^EUR	-27.59%

Current month	+93.33%
1 month	+93.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Latest news about AMGEN INC.

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	May. 28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	May. 28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	May. 28	RE
Supreme Court Holds Invalid Cholesterol Drug Patent That Covered Millions Of Undisclosed Antibodies	May. 27	AQ

More news

Quotes 5-day view

Date	Price	Change
24-05-29	0.021	-27.59%
24-05-28	0.029	-12.12%
24-05-27	0.033	-5.71%
24-05-24	0.035	-16.67%
24-05-23	0.042	+35.48%

Real-time BOERSE MUENCHEN

Last update May 29, 2024 at 04:25 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Goldman Sachs
WKN	GG4ZF8
ISIN	DE000GG4ZF82
Date issued	2024-03-07
Strike	450 $
Maturity	2024-08-16 (80 Days)
Parity	10 : 1
Emission price	0.02 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.073 €
Lowest since issue	0.011 €
Spread	0.1 €
Spread %	83.33%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Consensus: Amgen Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

300.2 USD

Average target price

316.3 USD

Spread / Average Target

+5.36%

Consensus